Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012393 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Robin Avanthay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology and Immunology IVI, Mittelhäusern, Switzerland. Hauptthemen laut MEDLINE: Influenza Vaccines, Orthomyxoviridae Infections, Administration, Intranasal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation (SNSF), Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Live-attenuated influenza vaccines (LAIV) offer advantages over the commonly used inactivated split influenza vaccines. However, finding the optimal balance between sufficient attenuation and immunogenicity has remained a challenge. We recently developed an alternative LAIV based on the 2009 pandemic H1N1 virus with a truncated NS1 protein and lacking PA-X protein expression (NS1(1–126)-ΔPAX). This virus showed a blunted replication and elicited a strong innate immune response. In the present study, we evaluated the efficacy of this vaccine candidate in the porcine animal model as a pertinent in vivo system. Immunization of pigs via the nasal route with the novel NS1(1–126)-ΔPAX LAIV did not cause disease and elicited a strong mucosal immune response that completely blocked replication of the homologous challenge virus in the respiratory tract. However, we observed prolonged shedding of our vaccine candidate from the upper respiratory tract. To improve LAIV safety, we developed a novel prime/boost vaccination strategy combining primary intramuscular immunization with a haemagglutinin-encoding propagation-defective vesicular stomatitis virus (VSV) replicon, followed by a secondary immunization with the NS1(1–126)-ΔPAX LAIV via the nasal route. This two-step immunization procedure significantly reduced LAIV shedding, increased the production of specific serum IgG, neutralizing antibodies, and Th1 memory cells, and resulted in sterilizing immunity against homologous virus challenge. In conclusion, our novel intramuscular prime/intranasal boost regimen interferes with virus shedding and transmission, a feature that will help combat influenza epidemics and pandemics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Virology and Immunology IVI, Mittelhäusern, Switzerland.
- Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
- Institute of Animal Pathology, COMPATH, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
- Department of Anatomy and Comparative Pathology, Veterinary Faculty, University of Murcia, Murcia, Spain.
ORCID-Profile: Gert Zimmer
Förderung
- Swiss National Science Foundation (SNSF)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Avanthay, R., Garcia-Nicolas, O., Ruggli, N., Grau-Roma, L., Párraga-Ros, E., Summerfield, A., & Zimmer, G. (2024). Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012393
Vancouver
Avanthay R, Garcia-Nicolas O, Ruggli N, Grau-Roma L, Párraga-Ros E, Summerfield A, et al. Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012393
BibTeX
@article{Avanthay2024,
author = {Avanthay, Robin and Garcia-Nicolas, Obdulio and Ruggli, Nicolas and Grau-Roma, Llorenç and Párraga-Ros, Ester and Summerfield, Artur and Zimmer, Gert},
title = {Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012393}
}
EUVIMED